The (Endo)Cannabinoid System in Multiple Sclerosis and Amyotrophic Lateral Sclerosis

International Review of Neurobiology

Volumn 82, Issue , 2007, Pages 171-186

  Centonze, Diego ^a,b   Rossi, Silvia ^a,b   Finazzi Agrò, Alessandro ^a   Bernardi, Giorgio ^a,b   Maccarrone, Mauro ^b,c  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^c UNIVERSITY OF TERAMO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOCANNABINOID; GLUTAMIC ACID;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL; DEGENERATIVE DISEASE; HUMAN; MICROGLIA; MULTIPLE SCLEROSIS; OXIDATIVE STRESS; PATHOLOGY; PHYSIOLOGY; REVIEW; SYNAPTIC TRANSMISSION;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; ENDOCANNABINOIDS; GLUTAMIC ACID; HUMANS; MICROGLIA; MULTIPLE SCLEROSIS; NEURODEGENERATIVE DISEASES; OXIDATIVE STRESS; SYNAPTIC TRANSMISSION;

EID: 34547292646     PISSN: 00747742     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0074-7742(07)82009-5     Document Type: Review

References (101)

1. Abood M.E., Rizvi G., Sallapudi N., and McAllister S.D. Activation of the CB1 cannabinoid receptor protects cultured mouse spinal neurons against excitotoxicity. Neurosci. Lett. 309 (2001) 197-201
2. Alexianu M.E., Kozovska M., and Appel S.H. Immune reactivity in a mouse model of familial ALS correlates with disease progression. Neurology 57 (2001) 1282-1289
3. Almer G., Vukosavic S., Romero N., and Przedborski S. Inducible nitric oxide synthase up-regulation in a transgenic mouse model of familial amyotrophic lateral sclerosis. J. Neurochem. 72 (1999) 2415-2425
4. Almer G., Guegan C., Teismann P., Naini A., Rosoklija G., Hays A.P., Chen C., and Przedborski S. Increased expression of the pro-inflammatory enzyme cyclooxygenase-2 in amyotrophic lateral sclerosis. Ann. Neurol. 49 (2001) 176-185
5. Baker D., Pryce G., Croxford J.L., Brown P., Pertwee R.G., Huffman J.W., and Layward L. Cannabinoids control spasticity and tremor in a multiple sclerosis model. Nature 404 (2000) 84-87
6. Baker D., Pryce G., Croxford J.L., Brown P., Pertwee R.G., Makriyannis A., Khanolkar A., Layward L., Fezza F., Bisogno T., and Di Marzo V. Endocannabinoids control spasticity in a multiple sclerosis model. FASEB J. 15 (2001) 300-302
7. Baker D., Pryce G., Giovannoni G., and Thompson A.J. The therapeutic potential of cannabis. Lancet Neurol. 2 (2003) 291-298
8. Bakshi R., Benedict R.H., Bermel R.A., Caruthers S.D., Puli S.R., Tjoa C.W., Fabiano A.J., and Jacobs L. T2 hypointensity in the deep gray matter of patients with multiple sclerosis: A quantitative magnetic resonance imaging study. Arch. Neurol. 59 (2002) 62-68
9. Bari M., Battista N., Fezza F., Gasperi V., and Maccarrone M. New insights into endocannabinoid degradation and its therapeutic potential. Mini-Rev. Med. Chem. 6 (2006) 109-120
10. Bendotti C., and Carrì M.T. Lessons from models of SOD1-linked familial ALS. Trends Mol. Med. 10 (2004) 393-400
11. Bermel R.A., Innus M.D., Tjoa C.W., and Bakshi R. Selective caudate atrophy in multiple sclerosis: A 3D MRI parcellation study. Neuroreport 14 (2003) 335-339
12. Bilsland L.G., Dick J.R., Pryce G., Petrosino S., Di Marzo V., Baker D., and Greensmith L. Increasing cannabinoid levels by pharmacological and genetic manipulation delay disease progression in SOD1 mice. FASEB J. 20 (2006) 1003-1005
13. Bjartmar C., Kinkel R.P., Kidd G., Rudick R.A., and Trapp B.D. Axonal loss in normal-appearing white matter in a patient with acute MS. Neurology 57 (2001) 1248-1252
14. Bolton C., and Paul C. MK-801 limits neurovascular dysfunction during experimental allergic encephalomyelitis. J. Pharmacol. Exp. Ther. 282 (1997) 397-402
15. Breivogel C.S., Griffin G., Di Marzo V., and Martin B.R. Evidence for a new G protein-coupled cannabinoid receptor in mouse brain. Mol. Pharmacol. 60 (2001) 155-163
16. Bruck W., and Stadelmann C. Inflammation and degeneration in multiple sclerosis. Neurol. Sci. 24 (2003) S265-S267
17. Bruijn L.I., Miller T.M., and Cleveland D.W. Unraveling the mechanisms involved in motor neuron degeneration in ALS. Annu. Rev. Neurosci. 27 (2004) 723-749
18. Cabranes A., Venderova K., de Lago E., Fezza F., Sanchez A., Mestre L., Valenti M., Garcia-Merino A., Ramos J.A., Di Marzo V., and Fernandez-Ruiz J. Decreased endocannabinoid levels in the brain and beneficial effects of agents activating cannabinoid and/or vanilloid receptors in a rat model of multiple sclerosis. Neurobiol. Dis. 20 (2005) 207-217
19. Carriedo S.G., Sensi S.L., Yin H.Z., and Weiss J.H. AMPA exposures induce mitochondrial Ca(2+) overload and ROS generation in spinal motor neurons in vitro. J. Neurosci. 20 (2000) 240-250
20. Chevaleyre V., Takahashi K.A., and Castello P.E. Endocannabinoid-mediated synaptic plasticity in the CNS. Annu. Rev. Neurosci. 29 (2006) 37-76
21. Consroe P. Brain cannabinoid systems as targets for the therapy of neurological disorders. Neurobiol. Dis. 6 (1998) 534-551
22. Croxford J.L., and Miller S.D. Immunoregulation of a viral model of multiple sclerosis using the synthetic cannabinoid R(+)WIN55,212-2,212. J. Clin. Invest. 111 (2003) 1231-1240
23. Curran N.M., Griffin B.D., O'Toole D., Brady K.J., Fitzgerald S.N., and Moynagh P.N. The synthetic cannabinoid R(+)WIN 55,212-2 inhibits the interleukin-1 signaling pathway in human astrocytes in a cannabinoid receptor-independent manner. J. Biol. Chem. 280 (2005) 35797-35806
24. De Stefano N., Narayanan S., Francio S.J., Smith S., Mortella M., Tartaglia M.C., Bartolozzi M.L., Guidi L., Federico A., and Arnold D.L. Diffuse axonal and tissue injury in patients with multiple sclerosis with low cerebral lesion load and no disability. Arch. Neurol. 59 (2002) 1565-1571
25. Doble A. The role of excitotoxicity in neurodegenerative disease: Implications for therapy. Pharmacol. Ther. 81 (1999) 163-221
26. Doherty J., and Dingledine R. Functional interactions between cannabinoid and metabotropic glutamate receptors in the central nervous system. Curr. Opin. Pharmacol. 3 (2003) 46-53
27. Drachman D.B., Frank K., Dykes-Hoberg M., Teismann P., Almer G., Przedborski S., and Rothstein J.D. Cyclooxygenase 2 inhibition protects motor neurons and prolongs survival in a transgenic mouse model of ALS. Ann. Neurol. 52 (2002) 771-778
28. Drmota T., Greasley P., and Groblewski T. Screening assays for cannabinoid-ligand-type modulators of GPR55 (2004) Patent WO 2004/074844 A1
29. Egertova M., Cravatt B.F., and Elphick M.R. Comparative analysis of fatty acid amide hydrolase and CB1 cannabinoid receptor expression in the mouse brain: Evidence of a widespread role for fatty acid amide hydrolase in regulation of endocannabinoid signaling. Neuroscience 119 (2003) 481-496
30. Ehrhart J., Obregon D., Mori T., Hou H., Sun N., Bai Y., Klein T., Fernandez F., Tan J., and Shytle R.D. Stimulation of cannabinoid receptor 2 (CB2) suppresses microglial activation. J. Neuroinflammation 2 (2005) 29-32
31. Eljaschewitsch E., Witting A., Mawrin C., Lee T., Schmidt P.M., Wolf S., Hoertnagl H., Raine C.S., Schneider-Stock R., Nitsch R., and Ullrich O. The endocannabinoid anandamide protects neurons during CNS inflammation by induction of MKP-1 in microglial cells. Neuron 49 (2006) 67-79
32. Facchinetti F., Del Giudice E., Furegato S., Passarotto M., and Leon A. Cannabinoids ablate release of TNFalpha in rat microglial cells stimulated with lypopolysaccharide. Glia 41 (2003) 161-168
33. Fernandez-Ruiz J., Lastres-Becker I., Cabranes A., Gonzalez S., and Ramos J.A. Endocannabinoids and basal ganglia functionality. Prostaglandins Leukot. Essent. Fatty Acids 66 (2002) 257-267
34. Filippi M., and Rocca M.A. MRI evidence for multiple sclerosis as a diffuse disease of the central nervous system. J. Neurol. 252 (2005) S16-S24
35. Filippi M., Bozzali M., Rovaris M., Gonen O., Kesavadas C., Ghezzi A., Martinelli V., Grossman R.I., Scotti G., Comi G., and Falini A. Evidence for widespread axonal damage at the earliest clinical stage of multiple sclerosis. Brain 126 (2003) 433-437
36. Galiegue S., Mary S., Marchand J., Dussossoy D., Carriere D., Carayon P., Bouaboula M., Shire D., Le Fur G., and Casellas P. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur. J. Biochem. 232 (1995) 54-61
37. Hall E.D., Andrus P.K., Oostveen J.A., Fleck T.J., and Gurney M.E. Relationship of oxygen radical-induced lipid peroxidative damage to disease onset and progression in a transgenic model of familial ALS. J. Neurosci. Res. 53 (1998) 66-77
38. Hampson A.J., Grimaldi M., Axelrod J., and Wink D. Cannabidiol and (-)Delta9-tetrahydrocannabinol are neuroprotective antioxidants. Proc. Natl. Acad. Sci. USA 95 (1998) 8268-8273
39. Hardin-Pouzet H., Krakowski M., Bourbonniere L., Didier-Bazes M., Tran E., and Owens T. Glutamate metabolism is down-regulated in astrocytes during experimental allergic encephalomyelitis. Glia 20 (1997) 79-85
40. Henkel J.S., Engelhardt J.I., Siklos L., Simpson E.P., Kim S.H., Pan T., Goodman J.C., Siddique T., Beers D.R., and Appel S.H. Presence of dendritic cells, MCP-1, and activated microglia/macrophages in amyotrophic lateral sclerosis spinal cord tissue. Ann. Neurol. 55 (2004) 221-235
41. Howlett A.C., Barth F., Bonner T.I., Cabral G., Casellas P., Devane W.A., Felder C.C., Herkenham M., Mackie K., Martin B.R., Mechoulam R., and Pertwee R.G. International union of pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol. Rev. 54 (2002) 161-202
42. Kawamata T., Akiyama H., Yamada T., and McGeer P.L. Immunologic reactions in amyotrophic lateral sclerosis brain and spinal cord tissue. Am. J. Pathol. 140 (1992) 691-707
43. Killestein J., and Uitdehaag B.M. Cannabinoids in multiple sclerosis: Urgent need for long term trials. J. Neurol. Neurosurg. Psychiatr. 76 (2005) 1612-1614
44. Klegeris A., Bissonnette C.J., and McGeer P.L. Reduction of human monocytic cell neurotoxicity and cytokine secretion by ligands of the cannabinoid-type CB2 receptor. Br. J. Pharmacol. 139 (2003) 775-786
45. Klein T.W., Newton C., Larsen K., Lu L., Perkins I., Nong L., and Friedman H. The cannabinoid system and immune modulation. J. Leukoc. Biol. 74 (2003) 486-496
46. Klivenyi P., Kiaei M., Gardian G., Calingasan N.Y., and Beal M.F. Additive neuroprotective effects of creatine and cyclooxygenase 2 inhibitors in a transgenic mouse model of amyotrophic lateral sclerosis. J. Neurochem. 88 (2004) 576-582
47. Kong J., and Xu Z. Massive mitochondrial degeneration in motor neurons triggers the onset of amyotrophic lateral sclerosis in mice expressing a mutant SOD1. J. Neurosci. 18 (1998) 3241-3250
48. Kozak K.R., and Marnett L.J. Oxidative metabolism of endocannabinoids. Prostaglandins Leukot. Essent. Fatty Acids 66 (2002) 211-220
49. Kuhlmann T., Lingfeld G., Bitsch A., Schuchardt J., and Bruck W. Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time. Brain 125 (2002) 2202-2212
50. Lassmann H. Axonal injury in multiple sclerosis. J. Neurol. Neurosurg. Psychiatr. 74 (2003) 695-697
51. Ligresti A., Cascio M.G., and Di Marzo V. Endocannabinoid metabolic pathways and enzymes. Curr. Drug Targets CNS Neurol. Disord. 4 (2005) 615-623
52. Lyman W.D., Sonett J.R., Brosnan C.F., Elkin R., and Bornstein M.B. Delta 9-tetrahydrocannabinol: A novel treatment for experimental autoimmune encephalomyelitis. J. Neuroimmunol. 23 (1989) 73-81
53. Maccarrone M., Valensise H., Bari M., Lazzarin N., Romanini C., and Finazzi-Agrò A. Progesterone up-regulates anandamide hydrolase in human lymphocytes: Role of cytokines and implications for fertility. J. Immunol. 166 (2001) 7183-7189
54. Maccarrone M., Fiori A., Bari M., Granata F., Gasperi V., De Stefano M.E., Finazzi-Agrò A., and Strom R. Regulation by cannabinoid receptors of anandamide transport across the blood-brain barrier and through other endothelial cells. Thromb. Haemost. 95 (2006) 117-127
55. Malfitano A.M., Matarese G., and Bifulco M. From cannabis to endocannabinoids in multiple sclerosis: A paradigm of central nervous system autoimmune diseases. Curr. Drug Targets CNS Neurol. Disord. 4 (2005) 667-675
56. Maragakis N.J., and Rothstein J.D. Glutamate transporters in neurologic disease. Arch. Neurol. 58 (2001) 365-370
57. Marinelli S., Di Marzo V., Berretta N., Matias I., Maccarrone M., Bernardi G., and Mercuri N.B. Presynaptic facilitation of glutamatergic synapses to dopaminergic neurons of the rat substantia nigra by endogenous stimulation of vanilloid receptors. J. Neurosci. 23 (2003) 3136-3144
58. McKinney M.K., and Cravatt B.F. Structure and function of fatty acid amide hydrolase. Annu. Rev. Biochem. 74 (2005) 411-432
59. Mestre L., Correa F., Arevalo-Martin A., Molina-Holgado E., Valenti M., Ortar G., Di Marzo V., and Guaza C. Pharmacological modulation of the endocannabinoid system in a viral model of multiple sclerosis. J. Neurochem. 92 (2005) 1327-1339
60. Nirmalananthan N., and Greensmith L. Amyotrophic lateral sclerosis: Recent advances and future therapies. Curr. Opin. Neurol. 18 (2005) 712-719
61. Nong L., Newton C., Friedman H., and Klein T.W. CB1 and CB2 receptor mRNA expression in human peripheral blood mononuclear cells (PBMC) from various donor types. Adv. Exp. Med. Biol. 493 (2001) 229-233
62. Nunez E., Benito C., Pazos M.R., Barbachano A., Fajardo O., Gonzalez S., Tolon R.M., and Romero J. Cannabinoid CB2 receptors are expressed by perivascular microglial cells in the human brain: An immunohistochemical study. Synapse 53 (2004) 208-213
63. Ohgoh M., Hanada T., Smith T., Hashimoto T., Ueno M., Yamanishi Y., Watanabe M., and Nishizawa Y. Altered expression of glutamate transporters in experimental autoimmune encephalomyelitis. J. Neuroimmunol. 125 (2002) 170-178
64. Ortega-Gutierrez S., Molina-Holgado E., Arevalo-Martin A., Correa F., Viso A., Lopez-Rodriguez M.L., Di Marzo V., and Guaza C. Activation of the endocannabinoid system as therapeutic approach in a murine model of multiple sclerosis. FASEB J. 19 (2005) 1338-1340
65. Pertwee R.G. Cannabinoids and multiple sclerosis. Pharmacol. Ther. 95 (2002) 165-174
66. Pertwee R.G., and Ross R.A. Cannabinoid receptors and their ligands. Prostaglandins Leukot. Essent. Fatty Acids 66 (2002) 101-121
67. Peterson J.W., Bo L., Mork S., Chang A., and Trapp B.D. Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions. Ann. Neurol. 50 (2001) 389-400
68. Piomelli D. The molecular logic of endocannabinoid signalling. Nat. Rev. Neurosci. 4 (2003) 873-884
69. Pitt D., Werner P., and Raine C.S. Glutamate excitotoxicity in a model of multiple sclerosis. Nat. Med. 6 (2000) 67-70
70. Plaut G.S. Effectiveness of amantadine in reducing relapses in multiple sclerosis. J. R. Soc. Med. 80 (1987) 91-93
71. Pompl P.N., Ho L., Bianchi M., McManus T., Qin W., and Pasinetti G.M. A therapeutic role for cyclooxygenase-2 inhibitors in a transgenic mouse model of amyotrophic lateral sclerosis. FASEB J. 17 (2003) 725-727
72. Pryce G., Ahmed Z., Hankey D.J., Jackson S.J., Croxford J.L., Pocock J.M., Ledent C., Petzold A., Thompson A.J., Giovannoni G., Cuzner M.L., and Baker D. Cannabinoids inhibit neurodegeneration in models of multiple sclerosis. Brain 126 (2003) 2191-2202
73. Puffenbarger R.A., Boothe A.C., and Cabral G.A. Cannabinoids inhibit LPS-inducible cytokine mRNA expression in rat microglial cells. Glia 29 (2000) 58-69
74. Raman C., McAllister S.D., Rizvi G., Patel S.G., Moore D.H., and Abood M.E. Amyotrophic lateral sclerosis: Delayed disease progression in mice by treatment with a cannabinoid. Amyotroph. Lateral Scler. Other Motor Neuron Disord. 5 (2004) 33-39
75. Rao S.D., and Weiss J.H. Excitotoxic and oxidative cross-talk between motor neurons and glia in ALS pathogenesis. Trends Neurosci. 27 (2004) 17-23
76. Rao S.D., Yin H.Z., and Weiss J.H. Disruption of glial glutamate transport by reactive oxygen species produced in motor neurons. J. Neurosci. 23 (2003) 2627-2633
77. Sarchielli P., Greco L., Floridi A., and Gallai V. Excitatory amino acids and multiple sclerosis: Evidence from cerebrospinal fluid. Arch. Neurol. 60 (2003) 1082-1088
78. Shen M., and Thayer S.A. Cannabinoid receptor agonists protect cultured rat hippocampal neurons from excitotoxicity. Mol. Pharmacol. 54 (1998) 459-462
79. Slanina K.A., and Schweitzer P. Inhibition of cyclooxygenase-2 elicits a CB1-mediated decrease of excitatory transmission in rat CA1 hippocampus. Neuropharmacology 49 (2005) 653-659
80. Smith T., Groom A., Zhu B., and Turski L. Autoimmune encephalomyelitis ameliorated by AMPA antagonists. Nat. Med. 6 (2000) 62-66
81. Srinivasan R., Sailasuta N., Hurd R., Nelson S., and Pelleetier D. Evidence of elevated glutamate in multiple sclerosis using magnetic resonance spectroscopy at 3 T. Brain 128 (2005) 1016-1025
82. Stevenson V.L., Leary S.M., Losseff N.A., Parker G.J., Barker G.J., Husmani Y., Miller D.H., and Thompson A.J. Spinal cord atrophy and disability in MS: A longitudinal study. Neurology 51 (1998) 234-238
83. Stover J.F., Pleines U.E., Morganti-Kossmann M.C., Kossmann T., Lowitzsch K., and Kempski O.S. Neurotransmitters in cerebrospinal fluid reflect pathological activity. Eur. J. Clin. Invest. 27 (1997) 1038-1043
84. Tikka T.M., Vartiainen N.E., Goldsteins G., Oja S.S., Andersen P.M., Marklund S.L., and Koistinaho J. Minocycline prevents neurotoxicity induced by cerebrospinal fluid from patients with motor neurone disease. Brain 125 (2002) 722-731
85. Turner M.R., Cagnin A., Turkheimer F.E., Miller C.C., Shaw C.E., Brooks D.J., Leigh P.N., and Banati R.B. Evidence of widespread cerebral microglial activation in amyotrophic lateral sclerosis: An [11C](R)-PK11195 positron emission tomography study. Neurobiol. Dis. 15 (2004) 601-609
86. Vallejo-Illarramendi A., Domercq M., Perez-Cerda F., Ravid R., and Matute C. Increased expression and function of glutamate transporters in multiple sclerosis. Neurobiol. Dis. 21 (2006) 154-164
87. Van Sickle M.D., Duncan M., Kingsley P.J., Mouihate A., Urbani P., Mackie K., Stella N., Makriyannis A., Piomelli D., Davison J.S., Marnett L.J., Di Marzo V., et al. Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science 310 (2005) 329-332
88. Vermeiren C., Hemptinne I., Vanhoutte N., Tilleux S., Maloteaux J.M., and Hermans E. Loss of metabotropic glutamate receptor-mediated regulation of glutamate transport in chemically activated astrocytes in a rat model of amyotrophic lateral sclerosis. J. Neurochem. 96 (2006) 719-731
89. 2+, mitochondria and selective motoneuron vulnerability: Implications for ALS. Trends Neurosci. 28 (2005) 494-500
90. Wallstrom E., Diener P., Ljungdahl A., Khademi M., Nilsson C.G., and Olsson T. Memantine abrogates neurological deficits, but not CNS inflammation, in Lewis rat experimental autoimmune encephalomyelitis. J. Neurol. Sci. 137 (1996) 89-96
91. Walter L., and Stella N. Cannabinoids and neuroinflammation. Br. J. Pharmacol. 141 (2004) 775-785
92. Werner P., Pitt D., and Raine C.S. Multiple sclerosis: Altered glutamate homeostasis in lesions correlates with oligodendrocyte and axonal damage. Ann. Neurol. 50 (2001) 169-180
93. Weydt P., Yuen E.C., Ransom B.R., and Moller T. Increased cytotoxic potential of microglia from ALS-transgenic mice. Glia 48 2 (2004) 179-182
94. Weydt P., Hong S., Witting A., Moller T., Stella N., and Kliot M. Cannabinol delays symptom onset in SOD1 (G93A) transgenic mice without affecting survival. Amyotroph. Lateral Scler. Other Motor Neuron Disord. 6 (2005) 182-184
95. Wirguin I., Mechoulam R., Breuer A., Schezen E., Weidenfeld J., and Brenner T. Suppression of experimental autoimmune encephalomyelitis by cannabinoids. Immunopharmacology 28 (1994) 209-214
96. Witting A., Weydt P., Hong S., Kliot M., Moller T., and Stella N. Endocannabinoids accumulate in spinal cord of SOD1 G93A transgenic mice. J. Neurochem. 89 (2004) 1555-1557
97. Witting A., Chen L., Cudaback E., Straiker A., Walter L., Rickman B., Moller T., Brosnan C., and Stella N. Experimental autoimmune encephalomyelitis disrupts endocannabinoid-mediated neuroprotection. Proc. Natl. Acad. Sci. USA 103 (2006) 6362-6367
98. Wong P.C., Pardo C.A., Borchelt D.R., Lee M.K., Copeland N.G., Jenkins N.A., Sisodia S.S., Cleveland D.W., and Price D.L. An adverse property of a familial ALS-linked SOD1 mutation causes motor neuron disease characterized by vacuolar degeneration of mitochondria. Neuron 14 (1995) 1105-1116
99. Yasojima K., Tourtellotte W.W., McGeer E.G., and McGeer P.L. Marked increase in cyclooxygenase-2 in ALS spinal cord: Implications for therapy. Neurology 57 (2001) 952-956
100. Yiangou Y., Facer P., Durrenberger P., Chessell I.P., Naylor A., Bountra C., Banati R.R., and Anand P. COX-2, CB2 and P2X7-immunoreactivities are increased in activated microglial cells/macrophages of multiple sclerosis and amyotrophic lateral sclerosis spinal cord. BMC Neurol. 6 (2006) 12
101. Zajicek J., Fox P., Sanders H., Wright D., Vickery J., Nunn A., Thompson A., and UK MS Research Group. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): Multicentre randomised placebo-controlled trial. Lancet 362 (2003) 517-526